Avanos Medical (AVNS) Q2 2024: Digestive Health Grows 9%, Margin Expansion Signals Transformation Traction
Digestive health delivered nearly 9 percent organic growth, powering margin expansion and reinforcing Avanos’ transformation thesis. Pain management and recovery gained momentum, but headwinds in HA and product rationalization tempered portfolio-wide growth. With operational discipline and targeted M&A, Avanos is positioned to deliver on its 2025 targets, though execution risks remain as end-market dynamics evolve.
Summary
- Digestive Health Outperformance: Category leadership and Neomed adoption drove outpaced organic growth.
- Portfolio Rationalization: Exiting lower-return products and optimizing SG&A underpinned margin gains.
- Transformation Milestones: Progress on cost, mix, and capital allocation strengthens path to 2025 objectives.
Business Overview
Avanos Medical is a medtech company focused on delivering products in digestive health and pain management and recovery. Revenue is generated through the sale of medical devices and consumables for long- and short-term feeding, neonatal care, surgical pain relief, and post-operative recovery. The business is organized around two primary segments: Digestive Health (feeding tubes, Neomed, and related products) and Pain Management & Recovery (OnQ, Ambit, Game Ready, and HA portfolios). Avanos has exited its respiratory health business, sharpening its focus on higher-margin, core categories.
Performance Analysis
Q2 results demonstrated the payoff from Avanos’ transformation priorities, with organic sales up 2.6 percent despite deliberate product exits and a planned decline in the HA (hyaluronic acid) portfolio. Digestive health, which represents the company’s largest and most profitable segment, posted nearly 9 percent organic growth, led by the Neomed product line and continued NFIT conversion in North America. The legacy central feeding business also contributed strong high single-digit growth, strengthening Avanos’ market leadership in feeding solutions.
The pain management and recovery segment showed mixed signals: core surgical pain (OnQ and Ambit) and IVP (interventional pain) posted mid-single-digit growth, and Game Ready notched a second consecutive quarter of double-digit gains. However, the HA portfolio declined more than 30 percent year over year as anticipated, flattening sequentially. Portfolio rationalization and operational discipline drove margin expansion, with adjusted EBITDA margin up 210 basis points and SG&A as a percentage of revenue down 210 basis points year over year.
- Digestive Health Leadership: Segment’s near 9 percent growth and Neomed double-digit expansion underscore durable demand and successful innovation.
- Transformation Leverage: Cost actions and product exits enabled 17 percent adjusted EBITDA growth and improved margin structure.
- Pain Business Momentum: OnQ, Ambit, and Game Ready portfolios are regaining share, though HA remains a drag on reported growth.
Free cash flow improved sharply year over year, but full-year expectations were trimmed to $70 million due to higher one-time charges and inventory. The balance sheet remains conservative, supporting both M&A and opportunistic buybacks as capital allocation levers.
Executive Commentary
"Our three-year transformation priorities continue to drive our execution. And our second quarter results provided further evidence that we can deliver within the ranges of the 2025 financial targets we established last year during our investor day."
Joe Woody, CEO
"Our adjusted EBITDA grew by 17% compared to a year ago, with adjusted EBITDA margin expansion of 210 basis points... This margin expansion was positively impacted by top-line growth, effective manufacturing and operations execution, and continued SG&A optimization efforts."
Michael Greiner, Senior Vice President, CFO and Chief Transformation Officer
Strategic Positioning
1. Digestive Health as Growth Engine
Digestive health is Avanos’ core profit and growth driver, with Neomed and legacy central feeding both delivering high single- and double-digit growth. The company is leveraging continued NFIT conversion, product innovation, and international expansion to sustain above-market performance. As Neomed’s conversion runway tapers, Avanos is leaning on product launches and targeted M&A to maintain momentum.
2. Pain Management Portfolio Optimization
Pain management and recovery is being reshaped for margin and growth, with OnQ and Ambit benefiting from a renewed commercial focus and ASC (ambulatory surgical center) channel strategy. The DEROS acquisition and Trident product launch are driving new account conversions, while Game Ready’s international uptake is broadening the segment’s reach. HA remains a headwind, but management expects stabilization and eventual low-single-digit growth as pricing normalizes.
3. Transformation and Cost Discipline
Avanos’ four transformation priorities—portfolio optimization, commercial focus, cost management, and capital discipline—are yielding tangible margin and cash flow gains. Exiting lower-return products and streamlining SG&A have allowed the company to offset inflation and HA price volatility, while maintaining gross margins near 60 percent. Manufacturing and office footprint optimization is ongoing, with further cost savings anticipated into 2025.
4. Capital Allocation and M&A Pipeline
With leverage below one times and $92 million in cash, Avanos is positioned for strategic M&A in digestive health and opportunistic share repurchases. The company’s M&A discipline is evident, with deals only pursued when technology and financial hurdles are met. Share repurchases are paused pending new board authorization, but remain a potential lever.
Key Considerations
This quarter marks continued validation of Avanos’ transformation strategy, but future growth will increasingly depend on execution in innovation, M&A, and commercial channels as legacy tailwinds fade.
Key Considerations:
- Digestive Health Sustainability: Neomed’s NFIT conversion is nearing maturity; sustaining high growth will require successful new launches and global expansion.
- Pain Portfolio Recovery: OnQ, Ambit, and Game Ready are rebounding, but HA remains a portfolio drag; ASC channel and reimbursement changes could alter the trajectory.
- Transformation Execution Risk: Continued margin gains hinge on further SG&A and manufacturing optimization, with inflation and supply chain volatility as persistent challenges.
- Capital Deployment Discipline: Robust M&A pipeline exists, but management is cautious on valuation and technology fit, prioritizing balance sheet strength over speed.
- Reimbursement and Regulatory Shifts: CMS reimbursement proposals for OnQ could restore lost volume, but timing and adoption rates remain uncertain.
Risks
Key risks include the digesting of post-conversion deceleration in Neomed, persistent HA pricing and volume headwinds, and the potential for reimbursement changes to fall short of expectations. Operational execution on cost and mix management is critical, as is the ability to close and integrate accretive M&A. Macro health system pressures and competitive intensity could also impact volume and pricing, especially in commoditized or legacy segments.
Forward Outlook
For Q3 2024, Avanos guided to:
- Adjusted gross margin of approximately 60 percent
- Continued SG&A improvement as a percentage of revenue
For full-year 2024, management reaffirmed guidance:
- Revenue of $685 million to $705 million (mid-single-digit organic growth)
- Adjusted gross margins between 59.5 percent and 60.5 percent
- SG&A as a percentage of revenue between 41 percent and 42 percent
- Adjusted EPS of $1.30 to $1.45
- Adjusted EBITDA margin improvement of at least 200 basis points
- Free cash flow of approximately $70 million (revised down from prior expectations)
Management highlighted several factors that shape the outlook:
- Digestive health expected to maintain above-market growth, aided by innovation and M&A
- HA portfolio to remain flat sequentially, with stabilization anticipated in 2025
Takeaways
Avanos’ transformation is delivering on margin and cash flow, but sustaining outperformance will require innovation, disciplined M&A, and successful navigation of reimbursement and regulatory shifts.
- Digestive Health Remains the Anchor: Continued outperformance in core feeding and Neomed, but growth rates will moderate as conversion winds down, shifting focus to launches and international.
- Margin Expansion Validates Cost Actions: SG&A and operational optimization are driving EBITDA and margin gains, but further improvement is needed to reach 2025 targets.
- Execution on M&A and Commercial Initiatives Will Be Key: Investors should watch for bolt-on deals, new product uptake, and reimbursement developments as next-stage growth catalysts.
Conclusion
Avanos delivered a quarter that underscores the impact of its transformation priorities, with digestive health growth and margin expansion offsetting portfolio headwinds. As the company approaches 2025 targets, the ability to sustain growth and execute on innovation, M&A, and channel strategies will determine long-term value creation.
Industry Read-Through
Avanos’ results highlight the premium placed on focused portfolio management and operational discipline in medtech. The successful exit of low-return businesses and investment in core growth areas mirrors a broader industry trend toward specialization and margin improvement. Reimbursement clarity, especially in pain management, remains a sector-wide wildcard, with CMS decisions poised to reshape competitive dynamics. For peers, Avanos’ disciplined M&A posture and cost management provide a template, but also signal that inorganic growth will be harder to achieve without clear technology and margin fit. Companies with exposure to feeding, pain, or ASC channels should watch Avanos’ next moves as a bellwether for sustainable growth and transformation execution in a shifting healthcare landscape.